Affordable Access

Access to the full text

Baclofen-induced Changes in the Resting Brain Modulate Smoking Cue Reactivity: A Double-blind Placebo-controlled Functional Magnetic Resonance Imaging Study in Cigarette Smokers

Authors
  • Ketcherside, Ariel
  • Jagannathan, Kanchana
  • Dolui, Sudipto
  • Hager, Nathan
  • Spilka, Nathaniel
  • Nutor, Chaela
  • Rao, Hengyi
  • Franklin, Teresa
  • Wetherill, Reagan
Type
Published Article
Journal
Clinical Psychopharmacology and Neuroscience
Publisher
Korean College of Neuropsychopharmacology
Publication Date
May 31, 2020
Volume
18
Issue
2
Pages
289–302
Identifiers
DOI: 10.9758/cpn.2020.18.2.289
PMID: 32329309
PMCID: PMC7242101
Source
PubMed Central
Keywords
License
Green

Abstract

Objective Smoking cue-(SC) elicited craving can lead to relapse in SC-vulnerable individuals. Thus, identifying treatments that target SC-elicited craving is a top research priority. Reduced drug cue neural activity is associated with recovery and is marked by a profile of greater tonic (resting) activation in executive control regions, and increased connectivity between executive and salience regions. Evidence suggests the GABA-B agonist baclofen can reduce drug cue-elicited neural activity, potentially through its actions on the resting brain. Based on the literature, we hypothesize that baclofen’s effects in the resting brain can predict its effects during SC exposure. Methods In this longitudinal, double blind, placebo-controlled neuropharmacological study 43 non-abstinent, sated treatment-seeking cigarette smokers (63% male) participated in an fMRI resting-state scan and a SC-reactivity task prior to (T1) and 3 weeks following randomization (T2; baclofen: 80 mg/day; n = 21). Subjective craving reports were acquired before and after SC exposure to explicitly examine SC-induced craving. Results Whole-brain full-factorial analysis revealed a group-by-time interaction with greater resting brain activation of the right dorsolateral prefrontal cortex (dlPFC) at T2 in the baclofen group (BAC) ( p FWEcorr = 0.02), which was associated with reduced neural responses to SCs in key cue-reactive brain regions; the anterior ventral insula and ventromedial prefrontal cortex ( p FWEcorr < 0.01). BAC, but not the placebo group reported decreased SC-elicited craving ( p = 0.02). Conclusion Results suggest that baclofen mitigates the reward response to SCs through an increase in tonic activation of the dlPFC, an executive control region. Through these mechanisms, baclofen may offer SC-vulnerable smokers protection from SC-induced relapse.

Report this publication

Statistics

Seen <100 times